Denglong Wu

2.2k total citations
87 papers, 1.5k citations indexed

About

Denglong Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Denglong Wu has authored 87 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 33 papers in Pulmonary and Respiratory Medicine and 25 papers in Cancer Research. Recurrent topics in Denglong Wu's work include Prostate Cancer Treatment and Research (27 papers), Cancer-related molecular mechanisms research (14 papers) and Ubiquitin and proteasome pathways (10 papers). Denglong Wu is often cited by papers focused on Prostate Cancer Treatment and Research (27 papers), Cancer-related molecular mechanisms research (14 papers) and Ubiquitin and proteasome pathways (10 papers). Denglong Wu collaborates with scholars based in China, United States and Taiwan. Denglong Wu's co-authors include Shengsong Huang, Gang Wu, Chengdang Xu, Zhendong Xiang, Junliang Li, Qiang Wu, Jinfu Zhang, Yuan Lu, Zhong Wu and Yuan‐Fang Zhang and has published in prestigious journals such as Journal of Clinical Investigation, SHILAP Revista de lepidopterología and Molecular Cell.

In The Last Decade

Denglong Wu

82 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Denglong Wu China 24 805 497 312 172 152 87 1.5k
Florian Jentzmik Germany 16 777 1.0× 694 1.4× 494 1.6× 249 1.4× 135 0.9× 35 1.4k
Elke Eltze Germany 19 713 0.9× 435 0.9× 511 1.6× 347 2.0× 62 0.4× 73 1.6k
Takehiko Segawa Japan 18 600 0.7× 225 0.5× 642 2.1× 144 0.8× 80 0.5× 61 1.3k
Haowen Jiang China 25 1.0k 1.2× 631 1.3× 434 1.4× 410 2.4× 76 0.5× 104 1.8k
Jie Jin China 24 676 0.8× 310 0.6× 849 2.7× 296 1.7× 171 1.1× 103 1.7k
Jeffrey A. Borgia United States 22 760 0.9× 339 0.7× 286 0.9× 110 0.6× 17 0.1× 104 1.5k
Junichi Inokuchi Japan 28 1.1k 1.4× 533 1.1× 1.0k 3.3× 401 2.3× 99 0.7× 161 2.4k
Antonio Hurtado‐Coll Canada 24 887 1.1× 608 1.2× 1.2k 4.0× 172 1.0× 26 0.2× 39 2.0k
Paul Toren Canada 19 425 0.5× 272 0.5× 681 2.2× 235 1.4× 73 0.5× 77 1.2k
Monica Rutigliano Italy 32 1.3k 1.6× 771 1.6× 1.2k 3.8× 163 0.9× 42 0.3× 50 2.2k

Countries citing papers authored by Denglong Wu

Since Specialization
Citations

This map shows the geographic impact of Denglong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Denglong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Denglong Wu more than expected).

Fields of papers citing papers by Denglong Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Denglong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Denglong Wu. The network helps show where Denglong Wu may publish in the future.

Co-authorship network of co-authors of Denglong Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Denglong Wu. A scholar is included among the top collaborators of Denglong Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Denglong Wu. Denglong Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lu, Renquan, Ying Wu, Yiwen Yao, et al.. (2025). TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression. Cancer Research. 85(19). 3689–3705.
2.
Wang, Licheng, Cu‐Tai Lu, Xinan Wang, & Denglong Wu. (2025). PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer. European Journal of Medicinal Chemistry. 296. 117829–117829. 2 indexed citations
3.
Wang, Tianlong, Miaojun Zhu, Fang Ding, et al.. (2025). Liquid biopsy based on multi-targeted capture of urinary tumor DNA combined with machine learning to detect urothelial carcinoma: a multicenter prospective study. International Urology and Nephrology. 58(4). 1291–1306.
4.
Li, Jintao, Denglong Wu, Yan Shao, et al.. (2025). Bilayer book- like decellularized extracellular matrix scaffold with bioactive coatings for rotator cuff repair. Materials Today Bio. 33. 102038–102038. 1 indexed citations
5.
Wang, Xinan, Chengdang Xu, Xi Chen, et al.. (2024). PRL-mediated STAT5B/ARRB2 pathway promotes the progression of prostate cancer through the activation of MAPK signaling. Cell Death and Disease. 15(2). 128–128. 5 indexed citations
6.
Yan, Weiwei, Yang Liu, Jiahui Chen, et al.. (2024). PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. Journal of Clinical Investigation. 134(18). 5 indexed citations
7.
Huang, Shengsong, Weiwei Yan, Qian Zhuang, et al.. (2023). Active DHEA uptake in the prostate gland correlates with aggressive prostate cancer. Journal of Clinical Investigation. 133(24). 22 indexed citations
8.
Tan, Qilong, Xiaobo Gao, Xuefeng Qiu, et al.. (2022). Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors. Oncogene. 41(42). 4754–4767. 5 indexed citations
9.
Yang, Tao, Ying Liu, Yuanyuan Gao, et al.. (2022). Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment. Cell Reports Medicine. 3(5). 100608–100608. 18 indexed citations
10.
Liu, Ying, Tao Yang, Chengdang Xu, et al.. (2022). The clinical efficacy and limitations of dutasteride-regulated abiraterone metabolism in abiraterone-resistant patients: a prospective single-arm clinical trial in Chinese patients. Translational Andrology and Urology. 11(8). 1169–1176. 1 indexed citations
11.
Yang, Tao, Si Zhang, Yuanyuan Gao, et al.. (2021). Tracing steroidogenesis in prostate biopsy samples to unveil prostate tissue androgen metabolism characteristics and potential clinical application. The Journal of Steroid Biochemistry and Molecular Biology. 210(202). 105859–105859. 7 indexed citations
12.
Xiang, Zhendong, Yin Sun, Bosen You, et al.. (2021). Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death. Cell Death and Disease. 12(1). 68–68. 13 indexed citations
13.
Wang, Yi, et al.. (2021). Increased CDC6 Expression Associates With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. Frontiers in Oncology. 11. 666418–666418. 10 indexed citations
14.
Zhang, Jun, et al.. (2020). <p>KLF16 Affects the MYC Signature and Tumor Growth in Prostate Cancer</p>. OncoTargets and Therapy. Volume 13. 1303–1310. 15 indexed citations
15.
Zhang, Wei, Donglin Ding, Zhenlin Huang, et al.. (2020). DNA Damage Promotes TMPRSS2-ERG Oncoprotein Destruction and Prostate Cancer Suppression via Signaling Converged by GSK3β and WEE1. Molecular Cell. 79(6). 1008–1023.e4. 31 indexed citations
16.
Wu, Gang, Zhendong Xiang, Chengdang Xu, et al.. (2019). KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN. Biomedicine & Pharmacotherapy. 114. 108793–108793. 27 indexed citations
17.
Gao, Xiaomei, Charles S. Dai, Shengsong Huang, et al.. (2018). Functional Silencing of HSD17B2 in Prostate Cancer Promotes Disease Progression. Clinical Cancer Research. 25(4). 1291–1301. 41 indexed citations
18.
Hong, Zong‐Yuan, et al.. (2016). Specific MAPK inhibitors prevent hyperglycemia-induced renal diseases in type 1 diabetic mouse model. Molecular and Cellular Biochemistry. 419(1-2). 1–9. 20 indexed citations
19.
Xie, Yingqiu, Tursonjan Tokay, Zhaxybay Zhumadilov, et al.. (2016). nMET, A New Target in Recurrent Cancer. Current Cancer Drug Targets. 16(7). 572–578. 3 indexed citations
20.
Liu, Weiwei, Ming Guan, Denglong Wu, et al.. (2004). Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients. European Urology. 47(4). 456–462. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian Jentzmik Breakdown of academic impact, for papers by Elke Eltze Breakdown of academic impact, for papers by Takehiko Segawa Breakdown of academic impact, for papers by Haowen Jiang Breakdown of academic impact, for papers by Jie Jin Breakdown of academic impact, for papers by Jeffrey A. Borgia Breakdown of academic impact, for papers by Junichi Inokuchi Breakdown of academic impact, for papers by Antonio Hurtado‐Coll Breakdown of academic impact, for papers by Paul Toren Breakdown of academic impact, for papers by Monica Rutigliano
Rankless by CCL
2026